

Robert Huddart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8906319/publications.pdf>

Version: 2024-02-01

59
papers

1,748
citations

430442

18
h-index

288905

40
g-index

60
all docs

60
docs citations

60
times ranked

2352
citing authors

#	ARTICLE	IF	CITATIONS
1	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 43-54.	5.1	303
2	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. <i>Nature Communications</i> , 2015, 6, 5973.	5.8	161
3	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	1.4	138
4	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	0.8	108
5	Somatic <i>KIT</i> mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literature. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 34-42.	1.5	83
6	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	0.8	83
7	Adaptive-Predictive Organ Localization Using Cone-Beam Computed Tomography for Improved Accuracy in External Beam Radiotherapy for Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 705-712.	0.4	79
8	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	0.8	77
9	Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors. <i>Neoplasia</i> , 2005, 7, 1047-1052.	2.3	70
10	Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. <i>European Urology</i> , 2018, 73, 828-831.	0.9	54
11	Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1022-1030.	0.4	51
12	Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuited for Radical Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 115-122.	0.4	48
13	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	5.8	43
14	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 492-499.	0.8	42
15	Familial ovarian germ cell cancer: Report and review. , 1999, 84, 43-46.		27
16	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. <i>Clinical Cancer Research</i> , 2019, 25, 4104-4116.	3.2	27
17	Radiographer-led online image guided adaptive radiotherapy: A qualitative investigation of the therapeutic radiographer role. <i>Radiography</i> , 2021, 27, 1085-1093.	1.1	25
18	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.4	23

#	ARTICLE	IF	CITATIONS
19	Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020, 10, e037134.	0.8	22
20	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). <i>Journal of Clinical Oncology</i> , 2022, 40, 2468-2478.	0.8	22
21	Patterns of recurrence after prostate bed radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 141, 174-180.	0.3	19
22	Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 412-424.	0.4	19
23	Defining Bowel Dose Volume Constraints for Bladder Radiotherapy Treatment Planning. <i>Clinical Oncology</i> , 2015, 27, 22-29.	0.6	18
24	<title>Phase one clinical trial of the use of focused ultrasound surgery for the treatment of soft-tissue tumors</title>. , 1998, , .		17
25	Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP. <i>Advances in Urology</i> , 2018, 2018, 1-6.	0.6	17
26	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020, 10, e041005.	0.8	16
27	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021, 27, 1882-1892.	3.2	15
28	Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 27-32.	0.9	14
29	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. <i>Cancer Medicine</i> , 2022, 11, 2801-2816.	1.3	14
30	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 459-468.	2.3	13
31	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa022.	1.4	11
32	Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set. <i>European Urology Open Science</i> , 2021, 33, 83-88.	0.2	11
33	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic "Rapid Review. <i>Clinical Oncology</i> , 2020, 32, 347-353.	0.6	10
34	Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure. <i>British Journal of Radiology</i> , 2015, 88, 20150208.	1.0	8
35	SPIRE "combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. <i>Trials</i> , 2018, 19, 216.	0.7	7
36	Prostate Radiotherapy: Evaluating the Effect of Bladder and Rectal Changes on Prostate Movement-A CT Study. <i>Trends in Medical Research</i> , 2006, 1, 55-65.	0.2	6

#	ARTICLE	IF	CITATIONS
37	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	1.1	5
38	Recent advances in testicular germ cell tumours. <i>Faculty Reviews</i> , 2021, 10, 67.	1.7	5
39	PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. <i>Journal of Clinical Oncology</i> , 2016, 34, 430-430.	0.8	5
40	EP-1566 MR-guided online adaptive radiotherapy: First experience in the UK. <i>Radiotherapy and Oncology</i> , 2019, 133, S845.	0.3	4
41	The PRISM Trial- First UK Experience of MRI-Guided Adaptive Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E301.	0.4	4
42	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1129-1138.	1.1	4
43	Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 458-465.e2.	0.9	3
44	Histological Features of Sporadic and Familial Testicular Germ Cell Tumors Compared and Analysis of Age-Related Changes of Histology. <i>Cancers</i> , 2021, 13, 1652.	1.7	3
45	Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy).. <i>Journal of Clinical Oncology</i> , 2014, 32, 291-291.	0.8	3
46	Toxicity and Survival Outcomes of a Randomized Phase 2 Trial of Hypofractionated Bladder Radiation Therapy in an Elderly Population With or Without Image Guided Adaptive Plan Selection (HYBRID -) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.4	3
47	PV-0461: Integrating diagnostic MRI in radical bladder cancer radiotherapy: Challenges in image registration. <i>Radiotherapy and Oncology</i> , 2017, 123, S245-S246.	0.3	1
48	Early Experience of Magnetic Resonance Sequence Evaluation Using an MR-Linac System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S130-S131.	0.4	1
49	EP-1613: Comparison of prostate delineation on multi-modality imaging for MR-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 127, S868-S869.	0.3	1
50	Abstract 2986: Meta-analysis of whole exome sequencing data reveals the mutational spectrum of testicular germ cell tumors. , 2015, , .		1
51	Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 21, 31-35.	0.6	1
52	Management of germ cell tumours of the testis. <i>Lancet, The</i> , 1999, 353, 410.	6.3	0
53	PD53-04 THE FEATURES AND MANAGEMENT OF LATE RELAPSE OF NON-SEMINOMATOUS GERM CELL TUMOURS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
54	EP-1363: Clinical efficacy of a dose escalated and hypofractionated pelvic IMRT study in prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, S731.	0.3	0

#	ARTICLE	IF	CITATIONS
55	EP-1370: Simultaneous integrated tumour boost planning in bladder cancer: a comparison of strategies. <i>Radiotherapy and Oncology</i> , 2017, 123, S734-S735.	0.3	0
56	Dose Mapping Local Failure Following Radical Image Guided Radiation Therapy to the Bladder and Pelvic Lymph Nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e83-e84.	0.4	0
57	Bladder Radiotherapy: Is Cinderella Ready for the Ball?. <i>Clinical Oncology</i> , 2021, 33, 343-345.	0.6	0
58	Reply to Santhanam Sundar and Paul Symonds's Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-15. <i>European Urology</i> , 2021, 80, e51-e52.	0.9	0
59	928: Bone Metastases from Testicular Tumours: Management and Outcomes. <i>Journal of Urology</i> , 2004, 171, 246-246.	0.2	0